Innate immune-oncology company Bolt Biotherapeutics expects to raise $230 million, and cancer cell therapy player Vor Biopharma expects to raise $176.9 million, in upsized initial public offerings (IPOs) starting today, following yesterday’s $587.5 million IPO for Sana Biotechnology and other financing news this week. Bolt is offering 11.5 million shares priced at $20 per share, after an earlier plan to offer 8.8 million shares priced between $16-$18. Meanwhile, Vor is offering 9.83 million shares priced at $18 each, raised from its original plan to sell 8.8 million shares priced between $16-$18.

Deerfield Management and the Dana-Farber Cancer Institute are at it again. Two years after teaming up on protein degradation R&D, the duo has inked a 10-year partnership aimed at turning scientific discoveries at Dana-Farber into new medicines and diagnostics for cancer.

After a quick pit stop at Verastem Oncology, Frank Neumann, M.D., Ph.D., has landed at Gilead Sciences’ Kite Pharma, where he will lead clinical development in blood cancers and solid tumors. His move follows a two-week tenure as Verastem’s chief medical officer, a post he left to work on cell therapy R&D.

All pharmaceutical products begin with an idea, followed by an array of complex steps required to bring the results of that idea to the commercial market.

Cynthia Collins is out as Editas Medicine’s CEO as chairman James Mullen takes over from Feb. 15 after the biotech lost its Allergan/AbbVie partnership on its leading eye disease drug EDIT-101.

The first Fabry disease patient treated with Avrobio’s plato gene therapy platform in a phase 2 trial has experienced the complete clearance of toxic kidney substrate.

Sanofi has revised the dosing scheme in its phase 3 assessment of RNAi drug fitusiran to reduce the risk of vascular thrombotic events in hemophilia patients. The revised scheme is intended to prevent the low levels of clot inhibitor antithrombin (AT) associated with vascular thrombotic events.

En route to its first human trial, Vor Biopharma raised $177 million in its Nasdaq debut. The IPO comes seven months after a $110 million venture round and will bankroll the development of its lead program, a cell therapy for acute myeloid leukemia (AML), as well as its earlier-stage pipeline.

23andMe is going public through a $3.5 billion deal spearheaded by Sir Richard Branson’s Virgin Group.

Massive private raise? Check. Preclinical pipeline? Check. Now, Sana Biotechnology is raising $587.5 million in a mammoth IPO that will bankroll the development of its cell engineering platforms and complete preclinical work for each of its early-stage, off-the-shelf cell therapies.